Stress Therapeutics, Inc.

Stress Therapeutics, Inc. is a for-profit corporate entity headquartered in San Diego, California, that specializes in developing innovative therapeutic candidates targeting the hypothalamic-pituitary-adrenal (HPA) axis for neurological and psychiatric conditions. Registered in SAM.gov since August 2009, the company focuses on developing first-in-class treatments to address chronic hyperactivity and dysregulation of the stress response system. The organization has been actively pursuing federal grant funding, primarily through Small Business Innovation Research (SBIR) programs, to advance its research and development of novel therapeutic approaches.

The company has received multiple federal grant awards from prominent National Institutes of Health agencies, specifically the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Aging (NIA). These grants have supported the development of therapeutic candidates for conditions such as Alcohol Use Disorder (AUD) and Alzheimer's Disease, with a consistent focus on modulating the HPA axis. The grants, totaling approximately $1.35 million, have funded critical research stages including lead optimization, investigational new drug (IND)-enabling studies, and preclinical efficacy testing. Each grant has emphasized the company's innovative approach to addressing HPA axis hyperactivity, with the ultimate goal of developing effective, long-term treatments that can normalize stress system responses and potentially mitigate neurological and psychiatric conditions by reducing excessive glucocorticoid release and restoring more physiological regulatory mechanisms.